E-viri
Recenzirano
-
van de Loosdrecht, Arjan A.; Ireland, Robin; Kern, Wolfgang; Della Porta, Matteo G.; Alhan, Canan; Balleisen, Jan Sebastian; Bettelheim, Peter; Bowen, David T.; Burbury, Kate; Eidenschink, Lisa; Cazzola, Mario; Chu, Spencer S. C.; Cullen, Matthew; Cutler, Jevon A.; Dräger, Angelika M.; Feuillard, Jean; Fenaux, Pierre; Font, Patricia; Germing, Ulrich; Haase, Detlef; Hellström-Lindberg, Eva; Johansson, Ulrika; Kordasti, Shahram; Loken, Michael R.; Malcovati, Luca; te Marvelde, Jeroen G.; Matarraz, Sergio; Milne, Timothy; Moshaver, Bijan; Mufti, Ghulam J.; Nikolova, Veselka; Ogata, Kiyoyuki; Oelschlaegel, Uta; Orfao, Alberto; Ossenkoppele, Gert J.; Porwit, Anna; Platzbecker, Uwe; Preijers, Frank; Psarra, Katherina; Richards, Stephen J.; Subirá, Dolores; Seymour, John F.; Tindell, Vicky; Vallespi, Teresa; Valent, Peter; van der Velden, Vincent H. J.; Wells, Denise A.; de Witte, Theo M.; Zettl, Florian; Béné, Marie C.; Westers, Theresia M.
Leukemia & lymphoma, 03/2013, Letnik: 54, Številka: 3Journal Article
Abstract An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.
